Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Transfus Apher Sci ; 62(2): 103662, 2023 Apr.
Article in English | MEDLINE | ID: covidwho-2301349

ABSTRACT

Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful substances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has expanded to a broad spectrum of hematological and non-hematological diseases due to various studies on the clinical efficacy of this procedure. In this context there are more than 30 centers performing therapeutic apheresis and registered in the apheresis database in Turkey. Herein, we, The Turkish Apheresis Registry, aimed to analyze some key articles published so far from Turkey regarding the use of apheresis for various indications.


Subject(s)
Blood Component Removal , Humans , Turkey , Blood Component Removal/methods , Registries , Databases, Factual
2.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis ; 2023.
Article in English | EuropePMC | ID: covidwho-2284981

ABSTRACT

Background The COVID-19 pandemic has led to emergency approval of treatment modalities unusual for viruses, such as therapeutic cytokine Hemadsorption(HA). This study aims to investigate the experience of salvage HA therapy and the effect of HA on routine laboratory tests. Methods Life-threatening COVID-19 patients followed up between April 2020 and October 2022 who underwent HA salvage therapy were retrospectively enrolled. Data derived from the medical records were evaluated to meet the assumptions of statistical tests, and those that met the relevant statistical rules were selected for further analysis. Tests of Wilcoxon, Paired-T, and repeated measures-ANOVA were used to analyse the laboratory tests performed before and after HA among the surviving and nonsurviving patients. P<0.05 was selected for the statistical significance of the alpha. Results A total of 55 patients were enrolled in the study. Fibrinogen(p=.007), lactate dehydrogenase (LDH)(p=0.021), C-reactive protein (CRP)(p<0.0001), and platelet (PLT)(p=0.046) levels showed a significant decrease with the HA effect. WBC(p=0.209), lymphocyte (p=0.135), procalcitonin (PCT)(p=0.424), ferritin(p=0.298), and D-dimer(p=0.391) levels were not affected by HA. Ferritin level was significantly affected by survival status(p=0.010). All patients tolerated HA well, and 16.4% (n=9) of the patients with life-threatening COVID-19 survived. Conclusion HA is well tolerated even when used as a last option. However, HA may not affect WBC, lymphocyte, and D-dimer levels. In contrast, the effect of HA could limit the benefits of LDH, CRP, and fibrinogen in various clinical assessments. This study suggests that HA treatment could be beneficial even if selected as a salvage therapy

3.
Transfus Apher Sci ; 62(3): 103701, 2023 Jun.
Article in English | MEDLINE | ID: covidwho-2284982

ABSTRACT

BACKGROUND: The COVID-19 pandemic has led to emergency approval of treatment modalities unusual for viruses, such as therapeutic cytokine Hemadsorption(HA). This study aims to investigate the experience of salvage HA therapy and the effect of HA on routine laboratory tests. METHODS: Life-threatening COVID-19 patients followed up between April 2020 and October 2022 who underwent HA salvage therapy were retrospectively enrolled. Data derived from the medical records were evaluated to meet the assumptions of statistical tests, and those that met the relevant statistical rules were selected for further analysis. Tests of Wilcoxon, Paired-T, and repeated measures-ANOVA were used to analyse the laboratory tests performed before and after HA among the surviving and nonsurviving patients. P < 0.05 was selected for the statistical significance of the alpha. RESULTS: A total of 55 patients were enrolled in the study. Fibrinogen (p = 0.007), lactate dehydrogenase (LDH) (p = 0.021), C-reactive protein (CRP) (p < 0.0001), and platelet (PLT) (p = 0.046) levels showed a significant decrease with the HA effect. WBC (p = 0.209), lymphocyte (p = 0.135), procalcitonin (PCT) (p = 0.424), ferritin (p = 0.298), and D-dimer (p = 0.391) levels were not affected by HA. Ferritin level was significantly affected by survival status (p = 0.010). All patients tolerated HA well, and 16.4 % (n = 9) of the patients with life-threatening COVID-19 survived. CONCLUSION: HA is well tolerated even when used as a last option. However, HA may not affect WBC, lymphocyte, and D-dimer levels. In contrast, the effect of HA could limit the benefits of LDH, CRP, and fibrinogen in various clinical assessments. This study suggests that HA treatment could be beneficial even if selected as a salvage therapy.


Subject(s)
COVID-19 , Humans , COVID-19/therapy , SARS-CoV-2/metabolism , Cytokines , Retrospective Studies , Salvage Therapy , Pandemics , Hemadsorption , C-Reactive Protein/analysis , Biomarkers
SELECTION OF CITATIONS
SEARCH DETAIL